ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Coronavirus Infections
Infections
Post-Acute COVID-19 Syndrome
Human Influenza
Pneumonia
Virus Diseases
Respiratory Tract Infections

COVID-19 trials near Cincinnati, OH, USA:

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who a...

Enrolling
COVID-19 Infection
Drug: remdesivir
Drug: placebo for ibuzatrelvir

Phase 3

Pfizer
Pfizer

Cincinnati, Ohio, United States and 116 other locations

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID...

Active, not recruiting
COVID-19
Biological: CVXGA (CVXGA50)
Biological: COMIRNATY®

Phase 2

Cyanvac

Cincinnati, Ohio, United States and 54 other locations

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID...

Active, not recruiting
COVID-19 Immunization
Influenza Immunization
Biological: RIV + rC19 (dose 3)
Biological: RIV + rC19 (dose 2)

Phase 1, Phase 2

Sanofi
Sanofi

Cincinnati, Ohio, United States and 11 other locations

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).In order to represent a more recently circulating SAR...

Active, not recruiting
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: VXA-CoV2-3.3

Phase 2

Vaxart

Cincinnati, Ohio, United States and 144 other locations

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19, ca-...

Active, not recruiting
COVID-19
SARS-COV-2 Infection
Biological: BNT162b2 (2025/2026 formulation)

Phase 3

BioNTech
BioNTech

Cincinnati, Ohio, United States and 30 other locations

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...

Enrolling
COVID-19
Parainfluenza
Drug: DAS181 COVID-19
Drug: DAS181

Phase 3

Ansun Biopharma

Cincinnati, Ohio, United States and 66 other locations

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most oft-...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Beavercreek, Ohio, United States and 217 other locations

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.Thi-...

Active, not recruiting
COVID-19
SARS-COV-2 Infection
Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

Phase 3

BioNTech
BioNTech

Cincinnati, Ohio, United States of America and 18 other locations

Safety and Immunogenicity of NVX-CoV2705 (COVID-19)

This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study resear-...

Active, not recruiting
COVID-19
SARS-CoV-2 Infection
Biological: NVX-CoV2705

Phase 3

Sanofi
Sanofi

Cincinnati, Ohio, United States and 9 other locations

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies ...

Enrolling
COVID-19
SARS-CoV-2 Virus
Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose

Phase 2, Phase 3

BioNTech
BioNTech

Cincinnati, Ohio, United States and 121 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems